Evidence map›Paper›PMID 30686120›Full record

ArticleCirculation research2019

Protective Effects of Activated Myofibroblasts in the Pressure-Overloaded Myocardium Are Mediated Through Smad-Dependent Activation of a Matrix-Preserving Program.

Ilaria Russo, Michele Cavalera, Shuaibo Huang, Ya Su, Anis Hanna, Bijun Chen, Arti V Shinde, Simon J Conway, Jonathan Graff, Nikolaos G Frangogiannis

Open access · bronzeAbstract read
In one paragraph

Article in Circulation research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed
12.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 129 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Antifibrotic Effects ofInternational journal of molecular sciences · 2026
    Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Liver diseases: epidemiology, causes, trends and predictions.Signal transduction and targeted therapy · 2025
    Review
  20. Review

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Ilaria RussoFrom the Division of Cardiology, Department of Medicine, Wilf Family Cardiovascular Research Institute, Albert Einstein College of Medicine, Bronx, NY (I.R., M.C., S.H., Y.S., A.H., B.C., A.V.S., N.G.F.).
Michele CavaleraFrom the Division of Cardiology, Department of Medicine, Wilf Family Cardiovascular Research Institute, Albert Einstein College of Medicine, Bronx, NY (I.R., M.C., S.H., Y.S., A.H., B.C., A.V.S., N.G.F.).
Shuaibo HuangFrom the Division of Cardiology, Department of Medicine, Wilf Family Cardiovascular Research Institute, Albert Einstein College of Medicine, Bronx, NY (I.R., M.C., S.H., Y.S., A.H., B.C., A.V.S., N.G.F.).
Ya SuFrom the Division of Cardiology, Department of Medicine, Wilf Family Cardiovascular Research Institute, Albert Einstein College of Medicine, Bronx, NY (I.R., M.C., S.H., Y.S., A.H., B.C., A.V.S., N.G.F.).
Anis HannaFrom the Division of Cardiology, Department of Medicine, Wilf Family Cardiovascular Research Institute, Albert Einstein College of Medicine, Bronx, NY (I.R., M.C., S.H., Y.S., A.H., B.C., A.V.S., N.G.F.).
Bijun ChenFrom the Division of Cardiology, Department of Medicine, Wilf Family Cardiovascular Research Institute, Albert Einstein College of Medicine, Bronx, NY (I.R., M.C., S.H., Y.S., A.H., B.C., A.V.S., N.G.F.).
Arti V ShindeFrom the Division of Cardiology, Department of Medicine, Wilf Family Cardiovascular Research Institute, Albert Einstein College of Medicine, Bronx, NY (I.R., M.C., S.H., Y.S., A.H., B.C., A.V.S., N.G.F.).
Simon J ConwayDepartment of Pediatrics, Indiana University, Indianapolis (S.J.C.).
Jonathan GraffDepartment of Developmental Biology, University of Texas Southwestern, Dallas (J.G.).
Nikolaos G FrangogiannisFrom the Division of Cardiology, Department of Medicine, Wilf Family Cardiovascular Research Institute, Albert Einstein College of Medicine, Bronx, NY (I.R., M.C., S.H., Y.S., A.H., B.C., A.V.S., N.G.F.).
Albert Einstein College of Medicine · USIndiana University – Purdue University Indianapolis · US

Funding

Chemokines in Healing Myocardial InfarctsR01HL076246 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI Nikolaos G Frangogiannis · 2005 to 2026
$9.5M
Resolution of Inflammation in healing Myocardial InfarctsR01HL085440 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI FRANGOGIANNIS, NIKOLAOS G · 2008 to 2025
$8.5M
Mechanisms of cardiac and pulmonary fibrosis in relation to TGF-beta signaling and miR-145 functionR01HL135657 · NHLBI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI CONWAY, SIMON JAMES, LILLY, BRENDA J · 2017 to 2020
$1.7M
QTRAP 5500 Triple Quadrupole Mass Spectrometer SystemS10RR027701 · NCRR · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI ANGELETTI, RUTH HOGUE · 2010 to 2010
$489k
NCRR NIH HHS S10 RR027701NHLBI NIH HHS R01 HL076246NHLBI NIH HHS R01 HL085440NHLBI NIH HHS R01 HL135657
6 · The paper itself

Abstract

rationaleThe heart contains abundant interstitial and perivascular fibroblasts. Traditional views suggest that, under conditions of mechanical stress, cytokines, growth factors, and neurohumoral mediators stimulate fibroblast activation, inducing ECM (extracellular matrix) protein synthesis and promoting fibrosis and diastolic dysfunction. Members of the TGF (transforming growth factor)-β family are upregulated and activated in the remodeling myocardium and modulate phenotype and function of all myocardial cell types through activation of intracellular effector molecules, the Smads (small mothers against decapentaplegic), and through Smad-independent pathways.

objectivesTo examine the role of fibroblast-specific TGF-β/Smad3 signaling in the remodeling pressure-overloaded myocardium. METHODS AND

resultsWe examined the effects of cell-specific Smad3 loss in activated periostin-expressing myofibroblasts using a mouse model of cardiac pressure overload, induced through transverse aortic constriction. Surprisingly, FS3KO (myofibroblast-specific Smad3 knockout) mice exhibited accelerated systolic dysfunction after pressure overload, evidenced by an early 40% reduction in ejection fraction after 7 days of transverse aortic constriction. Accelerated systolic dysfunction in pressure-overloaded FS3KO mice was associated with accentuated matrix degradation and generation of collagen-derived matrikines, accompanied by cardiomyocyte myofibrillar loss and apoptosis, and by enhanced macrophage-driven inflammation. In vitro, TGF-β1, TGF-β2, and TGF-β3 stimulated a Smad3-dependent matrix-preserving phenotype in cardiac fibroblasts, suppressing MMP (matrix metalloproteinase)-3 and MMP-8 synthesis and inducing TIMP (tissue inhibitor of metalloproteinases)-1. In vivo, administration of an MMP-8 inhibitor attenuated early systolic dysfunction in pressure-overloaded FS3KO mice, suggesting that the protective effects of activated cardiac myofibroblasts in the pressure-overloaded myocardium are, at least in part, because of suppression of MMPs and activation of a matrix-preserving program. MMP-8 stimulation induces a proinflammatory phenotype in isolated macrophages.

conclusionsIn the pressure-overloaded myocardium, TGF-β/Smad3-activated cardiac fibroblasts play an important protective role, preserving the ECM network, suppressing macrophage-driven inflammation, and attenuating cardiomyocyte injury. The protective actions of the myofibroblasts are mediated, at least in part, through Smad-dependent suppression of matrix-degrading proteases.

Indexed as

Stress, MechanicalVentricular RemodelingAnimalsCell Adhesion MoleculesExtracellular Matrix ProteinsMatrix Metalloproteinase 8Matrix Metalloproteinase InhibitorsMiceMice, KnockoutMyofibroblastsPressureSmad3 ProteinStroke VolumeTissue Inhibitor of Metalloproteinase-1Transforming Growth Factor beta1Transforming Growth Factor beta2Cell Adhesion MoleculesExtracellular Matrix ProteinsMatrix Metalloproteinase 8Matrix Metalloproteinase InhibitorsPOSTN protein, humanSmad3 ProteinSmad3 protein, mouseTIMP1 protein, humanTissue Inhibitor of Metalloproteinase-1Transforming Growth Factor beta1Transforming Growth Factor beta2Transforming Growth Factor beta3extracellular matrixfibroblastsinflammationmacrophagesmatrix metalloproteinases

Identifiers

PMID30686120
PMCPMC6459716
OpenAlexW2912288601

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.